| |
| Back to top |
|
 |
| |
Since joining Pfizer in 1987, Shama Kajiji has held leadership positions on many oncology projects including Multidrug Resistance, Ras signaling, Apoptosis, and inhibition of c-Met tyrosine kinase. Shama’s drug discovery and development experience encompasses small molecules and human antibodies, some of which successfully progressed to Phase 3 studies. She is listed as a co-inventor on 10 patents and has published extensively in peer-reviewed journals. In order to better integrate the business and scientific objectives of the company, she completed an Executive MBA from the University of Rhode Island in 1998. This business training plus her Discovery - Development experience with in-house candidates and external licensing opportunities prepared her for taking on the newly created role of leading the Attrition Analysis Office at Pfizer.
more |
|
| |
| |
 |
| |
Jasmin Patel is the Chief Operating Officer for the Indian pharma business of leading MNC Novartis. In his current role Dr. Patel is responsible for the set up and development of a new pharma business in India and which is expected to be the Launch Engine for select novel products from the Novartis pipeline. Prior to assuming these responsibilities Patel was the Head of Disease Area Strategy and M&A Assessments for 2 years at Novartis global headquarters in Basel.
more |
|
| |
| |
 |
| Rama Shankar focuses on setting up Quality Management Systems, increasing productivity, improving cycle time, quality, and eliminating waste within strategic processes. Rama holds an M.S. in Engineering Management from Northwestern University, Evanston, IL, and a B.S. in Mechanical Engineering from India. She is a Certified Six Sigma Black Belt, Certified Quality Auditor, Malcolm Baldridge Award Examiner and a certified Lean Trainer. She is also an adjunct professor at Illinois Institute of Technology, Chicago, IL. |
|
| |
| Back to top |
| For more information on contribution of articles to PharmaAsia, please click here. |
| |
| Back to top |
| |
| Back to top |
| |
| |
